CU20190058A7 - Composiciones de aminoácidos relacionadas con mejoras de la función hepática - Google Patents

Composiciones de aminoácidos relacionadas con mejoras de la función hepática

Info

Publication number
CU20190058A7
CU20190058A7 CU2019000058A CU20190058A CU20190058A7 CU 20190058 A7 CU20190058 A7 CU 20190058A7 CU 2019000058 A CU2019000058 A CU 2019000058A CU 20190058 A CU20190058 A CU 20190058A CU 20190058 A7 CU20190058 A7 CU 20190058A7
Authority
CU
Cuba
Prior art keywords
amino acid
liver function
acid compositions
compositions related
pharmaceutical compositions
Prior art date
Application number
CU2019000058A
Other languages
English (en)
Spanish (es)
Inventor
Raffi Afeyan
David Berry
Michael Hamill
Chung-Wei Lee
Harry Luithardt
Original Assignee
Axcella Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcella Health Inc filed Critical Axcella Health Inc
Publication of CU20190058A7 publication Critical patent/CU20190058A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0634—N-Acetyl-Cysteine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CU2019000058A 2016-12-19 2017-12-19 Composiciones de aminoácidos relacionadas con mejoras de la función hepática CU20190058A7 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662436073P 2016-12-19 2016-12-19
US201762443205P 2017-01-06 2017-01-06
US201762491773P 2017-04-28 2017-04-28
US201762545322P 2017-08-14 2017-08-14
US201762576267P 2017-10-24 2017-10-24
PCT/US2017/067345 WO2018118941A1 (en) 2016-12-19 2017-12-19 Amino acid compositions and methods for the treatment of liver diseases

Publications (1)

Publication Number Publication Date
CU20190058A7 true CU20190058A7 (es) 2020-02-04

Family

ID=60957469

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000058A CU20190058A7 (es) 2016-12-19 2017-12-19 Composiciones de aminoácidos relacionadas con mejoras de la función hepática

Country Status (22)

Country Link
US (7) US11129804B2 (enExample)
EP (1) EP3554492A1 (enExample)
JP (2) JP2020504108A (enExample)
KR (1) KR20190099242A (enExample)
CN (2) CN115814053A (enExample)
AU (1) AU2017382170B2 (enExample)
BR (1) BR112019012529A2 (enExample)
CA (1) CA3046551A1 (enExample)
CL (1) CL2019001686A1 (enExample)
CO (1) CO2019006291A2 (enExample)
CU (1) CU20190058A7 (enExample)
EC (1) ECSP19043710A (enExample)
IL (3) IL296614A (enExample)
JO (1) JOP20190146A1 (enExample)
MA (1) MA51451A (enExample)
MX (2) MX2019007351A (enExample)
PE (1) PE20191136A1 (enExample)
PH (1) PH12019501414A1 (enExample)
SG (1) SG10201913946WA (enExample)
TW (1) TWI777999B (enExample)
WO (1) WO2018118941A1 (enExample)
ZA (1) ZA201903580B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
WO2018201024A1 (en) 2017-04-28 2018-11-01 Axcella Health Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
US10682325B2 (en) 2017-08-14 2020-06-16 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
CN111295186A (zh) * 2017-08-14 2020-06-16 胺细拉健康公司 用于治疗神经元损伤的氨基酸组合物
CN112839528A (zh) * 2018-04-18 2021-05-25 独创成分有限合伙公司 用于促进肌肉生长和功能的组合物及其使用方法
MA52957A (fr) 2018-06-20 2021-04-28 Axcella Health Inc Procédés de fabrication de compositions d'acides aminés
JP2021527670A (ja) 2018-06-20 2021-10-14 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． 筋肉中の脂肪浸潤の治療のための組成物及び方法
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
WO2020154397A1 (en) * 2019-01-22 2020-07-30 The Regents Of The University Of California Bile acids and use in disease treatment
CN110037221A (zh) * 2019-05-28 2019-07-23 广州阿米乐生物技术有限公司 一种解酒固体饮料及其制备方法
KR102401535B1 (ko) * 2019-07-30 2022-05-24 주식회사 고바이오랩 간 손상 예방, 개선, 또는 치료용 조성물
US12274718B2 (en) 2019-07-30 2025-04-15 Kobiolabs, Inc. Composition and method for preventing, alleviating, or treating liver injury
WO2021133948A1 (en) * 2019-12-23 2021-07-01 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders
AU2020436811B2 (en) * 2020-03-16 2024-07-04 Wuhan Vast Conduct Science Foundation Co., Ltd. Gold clusters (AuCs), composition and method for treatment of liver cirrhosis
WO2021184807A1 (en) * 2020-03-16 2021-09-23 Wuhan Vast Conduct Science Foundation Co., Ltd. Copper clusters, composition, and method for treatment of liver cirrhosis
AU2020446817A1 (en) * 2020-05-15 2023-01-19 Beijing Guanghe Original Technology Co., Ltd. Amino acid composition and method for catalytic synthesis of amino acid by means of energy radiation
US11938152B2 (en) 2020-08-06 2024-03-26 Kedar N Prasad High-dose antioxidants in cancer treatment
CN112394178B (zh) * 2020-11-16 2022-08-05 首都医科大学附属北京朝阳医院 莫西沙星相关肝损伤的生物标志物、试剂盒及应用
WO2022266480A1 (en) 2021-06-17 2022-12-22 Axcella Health Inc. Methods of predicting liver fat content and uses thereof
WO2023009444A1 (en) * 2021-07-26 2023-02-02 Axcella Health Inc. Amino acid compositions and methods for use in the treatment of post-acute sequelae of covid-19
US20250268855A1 (en) * 2022-04-25 2025-08-28 Fundació Eurecat Pharmaceutical and nutraceutical compositions with a combination of amino acids and its use in diseases characterized by lipid accumulation in tissues
WO2024026307A1 (en) 2022-07-25 2024-02-01 Axcella Health Inc. Biomarker for long covid and fatigue
WO2024030909A1 (en) 2022-08-01 2024-02-08 Axcella Health Inc. Biomarkers of amino acid composition treatment response in long covid
WO2024186730A1 (en) * 2023-03-03 2024-09-12 Grads Innovation Compositions for enhanced metabolic oxidation of fatty acids

Family Cites Families (333)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US693094A (en) 1900-08-13 1902-02-11 Hall Signal Co Signal and signaling-circuit.
US2457820A (en) 1945-12-27 1949-01-04 Merck & Co Inc Amino acid solution and process for preparing the same
US3012924A (en) 1956-12-17 1961-12-12 Libbey Owens Ford Glass Co Electrically conducting unit
GB1034358A (en) 1963-05-01 1966-06-29 Chugai Pharmaceutical Co Ltd Body-protein-biosynthesis promoting composition
US3832465A (en) 1971-12-09 1974-08-27 H Ghadimi Injectable amino acid composition commensurate to the anabolic need of the body and method of using same
US3988466A (en) 1973-06-01 1976-10-26 Kyowa Hakko Kogyo Co., Ltd. Prevention of gastric lesions
US3950529A (en) 1975-02-03 1976-04-13 Massachusetts General Hospital Amino acid formulations for patients with liver disease and method of using same
JPS5535049A (en) 1978-09-04 1980-03-11 Otsuka Pharmaceut Factory Inc Amino acid transfusion for cancerous patient
DE2906034C2 (de) 1979-02-16 1985-03-28 Maggi AG, Kempttal Verfahren zur Gewinnung von L-Leucin, L-Phenylalanin, L-Tyrosin, L-Cystin und von Gemischen aus L-Leucin und L-Isoleucin
CA1184499A (en) 1981-06-29 1985-03-26 David C. Madsen Nutritional composition for management of hepatic failure
US4898879A (en) 1981-06-29 1990-02-06 Baxter International Inc. Nurtitional composition for management of hepatic failure
JPS58126767A (ja) 1982-01-22 1983-07-28 Ajinomoto Co Inc 肝臓病患者用栄養組成物
US5298493A (en) 1983-04-20 1994-03-29 Clintec Nutrition Co. Compound for use in dietetics, reanimation and therapeutics containing protein fractions based on three types of minipeptides
CH658165A5 (fr) 1984-01-04 1986-10-31 Nestle Sa Produit alimentaire efficace dans le traitement de la lepre.
US5034377A (en) 1984-11-19 1991-07-23 Montefiore Hospital Association Of Western Pennsylvania Aqueous nutrient compositions comprising oligopeptides
JPS61186320A (ja) * 1985-02-12 1986-08-20 Morishita Seiyaku Kk アミノ酸製剤
US4871550A (en) 1986-09-05 1989-10-03 Millman Phillip L Nutrient composition for athletes and method of making and using the same
FR2618331B1 (fr) 1987-07-23 1991-10-04 Synthelabo Compositions pharmaceutiques utiles pour le traitement de l'uremie
US5028622A (en) 1988-05-06 1991-07-02 Ajinomoto Company, Inc. Administration of amino acids as treatment for neurodegenerative disorders
US5576351A (en) 1989-12-29 1996-11-19 Mcgaw, Inc. Use of arginine as an immunostimulator
EP0486425B1 (en) 1990-11-01 1994-08-31 Sandoz Nutrition Ltd. High acid system nutritional formulations
US5106836A (en) 1991-02-22 1992-04-21 Clintec Nutrition Co. Enteral diet
US5977073A (en) 1991-06-06 1999-11-02 Life Sciences' Technologies, Inc. Nutrient composition for treatment of immune disorders
US5780039A (en) 1992-04-23 1998-07-14 Novartis Nutrition Ag Orally-ingestible nutrition compositions having improved palatability
US5229136A (en) 1992-05-21 1993-07-20 Clintec Nutrition Co. Low caloric density enteral formulation designed to reduce diarrhea in tube-fed patients
US5276018A (en) 1992-07-17 1994-01-04 Brigham And Women's Hospital Composition comprising amino acids and methods for decreasing muscle breakdown
DE4229166A1 (de) 1992-09-01 1994-03-03 Deutsches Krebsforsch Mittel zur Aufrechterhaltung und/oder Steigerung der Muskelleistung und Körperzellmasse
US5356873A (en) 1992-11-05 1994-10-18 Clintec Nutrition Co. Method for providing nutritional requirements to patients having a chronic inflammation reaction
US5348979A (en) * 1992-12-23 1994-09-20 Iowa State University Research Foundation Inc. Method of promoting nitrogen retention in humans
ES2173109T3 (es) 1992-12-23 2002-10-16 Abbott Lab Alimentos de unso medico destinados parael sostenimiento nutricional de recien nacidos/de bebes que padecen enfermedades metabolicas.
US5571783A (en) 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
US5891459A (en) 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
WO1995004529A1 (en) 1993-08-10 1995-02-16 Musashi Pty. Ltd. Composition for treatment of hangovers
US5438042B1 (en) 1993-10-08 1997-08-26 Sandoz Nutrition Ltd Enteral nutritional composition having amino acid profile
AU682894B2 (en) 1993-10-28 1997-10-23 Institut National De La Recherche Agronomique Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man
US5378722A (en) 1993-12-03 1995-01-03 Clintec Nutrition Co. Nutritional compositions for management of nitrogen metabolism
US5714472A (en) 1993-12-23 1998-02-03 Nestec Ltd. Enternal formulation designed for optimized nutrient absorption and wound healing
US5723446A (en) 1993-12-23 1998-03-03 Nestec Ltd. Enteral formulation designed for optimized nutrient absorption and wound healing
GB9403935D0 (en) 1994-03-01 1994-04-20 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
US5719133A (en) 1994-09-21 1998-02-17 Novartis Nutrition Ag Adolescent dietary composition
IT1275434B (it) 1995-05-19 1997-08-07 Farmila Farma Milano Composizioni farmaceutiche e/o dietetiche ad attivita' antiossidante
US5728678A (en) 1995-06-06 1998-03-17 Nestec Ltd. Method and composition for providing nutrition to a renal failure patient
JP4280310B2 (ja) 1995-08-10 2009-06-17 佐々木化学工業株式会社 アミノ酸組成剤
US5733884A (en) 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
US6087398A (en) 1996-03-01 2000-07-11 South Alabama Medical Science Foundation Sickle cell anemia treatment
US5716926A (en) 1996-07-26 1998-02-10 Paxton K. Beale Composition of pyruvate and protein and method for increasing protein concentration in a mammal
US6096785A (en) 1996-07-30 2000-08-01 Novartis Nutrition Ag Amino acid compositions and use thereof in treating renal dysfunction
JPH1053521A (ja) 1996-08-12 1998-02-24 Kagaku Gijutsu Shinko Jigyodan 脳内グルタミン酸の活性抑制剤および活性増強剤
US6544260B1 (en) 1996-08-20 2003-04-08 Oratec Interventions, Inc. Method for treating tissue in arthroscopic environment using precooling and apparatus for same
IT1289754B1 (it) 1996-12-16 1998-10-16 Professional Dietetics Srl Composizioni a base di aminoacidi
US6013273A (en) 1997-01-27 2000-01-11 Novartis Nutrition Ag Treatment of endotoxic shock
US5817329A (en) 1997-02-28 1998-10-06 Gardiner; Paul T. Nutritional supplement for increased muscle size and strength for body builders
EP1123013A1 (en) 1997-06-02 2001-08-16 Société des Produits Nestlé S.A. Product and method for providing glutamine
US5849335A (en) 1997-06-02 1998-12-15 Nestec S.A. Composition and method for providing glutamine
CA2239582C (en) 1997-06-05 2008-04-22 Novartis Nutrition Ag A new therapeutic use for glycine
US6281244B1 (en) 1997-06-05 2001-08-28 Novartis Nutrition Ag Therapeutic use for glycine
EP0891719A1 (en) 1997-07-14 1999-01-20 N.V. Nutricia Nutritional composition containing methionine
IT1294227B1 (it) 1997-08-01 1999-03-24 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l-carnitina e alcoli alifatici a lunga catena utile per la prevenzione
TW473387B (en) 1997-09-30 2002-01-21 Chugai Pharmaceutical Co Ltd Pharmaceutical or food compositions for treating hepatic diseases or improving liver functions
US6288116B1 (en) 1998-05-13 2001-09-11 Novartis Nutrition Ag Method of administration of a nutritional product to a person having renal failure
US6203820B1 (en) 1998-05-28 2001-03-20 Brice E. Vickery Compositions and methods for enhancing protein anabolism and detoxification
US6103748A (en) 1998-06-19 2000-08-15 Bryan; Thomas B. Method of treating an autoimmune disorder
US6031000A (en) 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
JP2000072669A (ja) 1998-08-24 2000-03-07 Inst Of Physical & Chemical Res アミノ酸・糖組成物
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US20010041187A1 (en) 1998-10-20 2001-11-15 Carl W Hastings Performance-enhancing dietary supplement
EP1004302A3 (en) 1998-10-29 2003-06-04 Ajinomoto Co., Inc. Immunomodulator
US6051236A (en) 1998-11-12 2000-04-18 Pacifichealth Laboratories, Inc. Composition for optimizing muscle performance during exercise
US6143786A (en) 1999-02-02 2000-11-07 Novartis Nutrition Ag Oral arginine and insulin secretion
US6241996B1 (en) 1999-04-09 2001-06-05 Novartis Nutrition Ag Liquid soy nutritional products
AU4280600A (en) 1999-04-27 2000-11-10 International Health Products And Services Ltd. Supplement for restoring growth hormone levels
AU8003800A (en) 1999-10-08 2001-04-23 Joyce Corinne Bechthold Methods and compositions for treating neurobehavioral disorders
GB9929497D0 (en) 1999-12-14 2000-02-09 Vitaflo Limited Improved amino acid mixtures for the treatment and/or management of certain diseases
CZ20022927A3 (cs) * 2000-02-01 2003-06-18 Muscletech Research And Development Inc. Doplňky stravy založené na alfa-lipoové kyselině pro zvýšení čisté svalové hmoty a síly
US6833350B2 (en) 2000-02-04 2004-12-21 Nestec S.A. Method for maintaining or improving the synthesis of mucins
US6521591B1 (en) 2000-02-10 2003-02-18 N.V. Nutricia Pharmaceutical composition for muscular anabolism
GB0009056D0 (en) 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
CN1423528A (zh) 2000-04-18 2003-06-11 雀巢制品公司 营养单元
US6391332B1 (en) 2000-04-20 2002-05-21 Baxter International, Inc. Therapeutic micronutrient composition for severe trauma, burns and critical illness
US20030187049A1 (en) 2000-07-04 2003-10-02 Dioguardi Francesco Saverio Compositions based on aminoacids, suitable for improving muscle performance
IT1320783B1 (it) 2000-07-04 2003-12-10 Professional Dietetics Srl Composizioni a base di aminoacidi, atte al miglioramento delleprestazioni muscolari.
IT1320782B1 (it) 2000-07-04 2003-12-10 Professional Dietetics Srl Composizioni a base di aminoacidi, atte al trattamentodell'insufficienza cardiaca.
US6417293B1 (en) 2000-12-04 2002-07-09 Dow Corning Corporation Thermoplastic silicone elastomers formed from polyester resins
DE10060819A1 (de) 2000-12-07 2002-06-13 Cognis Deutschland Gmbh Verwendung von Polyetheramin-Derivaten zur dauerhaften Verbesserung der Klebstoff- und/oder Beschichtungs-Kompatibilität von Polyethylen-basierten Formkörpern, Fasern und Folien
DE10060818A1 (de) 2000-12-07 2002-06-13 Cognis Deutschland Gmbh Verwendung von Polyetheraminen zur dauerhaften Verbesserung der Klebstoff- und/oder Beschichtungs-Kompatibilität von Polyethylen-basierten Formkörpern, Fasern und Folien
US6864242B2 (en) 2001-03-05 2005-03-08 Stephen P. Ernest Enteral formulation
US20040192751A1 (en) 2001-03-15 2004-09-30 Takeshi Abe Amino acid composition for ameliorating liver failure
US20020193342A1 (en) 2001-05-09 2002-12-19 Hamman John P. Modifying undesirable tastes
ITTO20010580A1 (it) 2001-06-15 2002-12-15 Professional Dietetics Srl Composizioni a base di aminoacidi per il miglioramento della funzioneventricolare miocardica in pazienti affetti da diabete.
US6864230B2 (en) 2001-07-31 2005-03-08 Novartis Nutrition Ag Glutamine rich dietary composition
WO2003055481A1 (en) 2001-12-25 2003-07-10 Ajinomoto Co., Inc. Organ fibrosis inhibitors
AU2003201579B2 (en) 2002-01-25 2008-07-24 Diamedica Inc. Use of glutathione synthesis stimulating compounds in reducing insulin resistance
JP2003238401A (ja) 2002-02-20 2003-08-27 Ajinomoto Co Inc 疾患の治療、改善又は予防用医薬品及び飲食品
US20050176827A1 (en) 2002-05-10 2005-08-11 Lee Steve S. Compositions and methods for glycogen synthesis
US7338675B2 (en) 2002-05-10 2008-03-04 Tsi Health Sciences, Inc. Fenugreek seed bio-active compositions and methods for extracting same
EP1549299B1 (en) 2002-06-05 2014-08-20 IVAX Pharmaceuticals s.r.o. Reduction of gelatin cross-linking
WO2004019928A1 (ja) 2002-08-30 2004-03-11 Ajinomoto Co., Inc. 肝疾患治療剤
US20040087490A1 (en) 2002-09-20 2004-05-06 Troup John P. Nutritional compositions
US20040057983A1 (en) 2002-09-25 2004-03-25 David Schmidt Biomolecular wearable apparatus
US7037522B2 (en) 2002-09-27 2006-05-02 Western Holdings, L.L.C. Nocturnal muscle enhancing composition and method
JP2004123564A (ja) 2002-09-30 2004-04-22 Inst Of Physical & Chemical Res 中枢機能改善用アミノ酸組成物
JP2004182705A (ja) 2002-10-11 2004-07-02 Yasutoshi Koga ミトコンドリア機能異常に起因する疾患における臨床症状発現の予防・治療用組成物
US7547450B2 (en) 2002-10-24 2009-06-16 Nestec Ltd. Senior feline food
US8093292B2 (en) 2002-11-22 2012-01-10 Bionexus, Ltd. Methods for the treatment of HIV-1 related fat maldistribution, fasting hyperlipidemia and modification of adipocyte physiology
US7288570B2 (en) 2002-12-20 2007-10-30 Nutricia N.V. Stimulation of in vivo production of proteins
US20040120983A1 (en) 2002-12-23 2004-06-24 Philip Connolly Nutritional supplement
CN101108001B (zh) 2002-12-26 2011-12-14 味之素株式会社 保健功能食品
JP4989836B2 (ja) 2002-12-26 2012-08-01 大塚製薬株式会社 経口栄養剤
JP2006520335A (ja) 2003-03-18 2006-09-07 ノバルティス アクチエンゲゼルシャフト 脂肪酸とアミノ酸を含有する組成物
US20040213838A1 (en) 2003-04-24 2004-10-28 Mazer Terrence B. Medical food tablets containing free amino acids
JP4528925B2 (ja) 2003-05-30 2010-08-25 独立行政法人理化学研究所 アミノ酸組成物及び補液
EP1638418B1 (en) 2003-06-23 2012-08-29 Nestec S.A. Amino acid supplementation for a healthy microbiota ecosystem
JP2005027524A (ja) 2003-07-08 2005-02-03 Ajinomoto Co Inc 経口アミノ酸組成物
WO2005017094A2 (en) 2003-08-19 2005-02-24 Bioadvantex Pharma Inc. N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency
ITTO20030789A1 (it) 2003-10-07 2005-04-08 Professional Dietetics Srl Composizione a base di amino acidi per il trattamento
CA2542652C (en) 2003-10-16 2014-05-13 Nestec S.A. Nutritional composition against side effects of chemotherapy or radiotherapy
WO2005049006A1 (ja) 2003-11-21 2005-06-02 Ajinomoto Co., Inc. 糖尿病治療剤
DK1543735T3 (en) 2003-12-20 2015-11-02 Nestec Sa FOOD COMPOSITION FOR HEALTH CARE
WO2005072721A1 (ja) 2004-01-28 2005-08-11 Ajinomoto Co., Inc. 局所脳血流低下に伴う神経系障害の予防または治療のための医薬組成物
WO2005082163A1 (ja) 2004-02-27 2005-09-09 Incorporated Administrative Agency National Agriculture And Food Research Organization 遊離アミノ酸を富化した食品素材及びその製造法
US20050233013A1 (en) * 2004-03-02 2005-10-20 Lee Steve S Methods for enhancing the transport of glucose for balancing blood sugar levels
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
JP4815752B2 (ja) 2004-04-01 2011-11-16 味の素株式会社 アミノ酸含有飲食品
WO2005110124A1 (en) 2004-04-15 2005-11-24 Abbott Laboratories Composition and methods for nutritional management of patients with hepatic disease
CN1582912A (zh) 2004-06-10 2005-02-23 武汉启瑞科技发展有限公司 L－鸟氨酸和 l－门冬氨酸组合物
WO2006009975A2 (en) 2004-06-22 2006-01-26 Maxim Pharmaceuticals, Inc. Histamine to treat disorders affecting muscle function
RU2372900C2 (ru) 2004-07-14 2009-11-20 Адзиномото Ко., Инк. Ингибитор возникновения и развития рака печени для применения у пациентов-людей с циррозом печени, положительных по вирусу гепатита с
DK1771191T3 (da) 2004-07-19 2014-06-10 Nutricia Nv Præparat til anvendelse af aspartat og B12-vitamin eller biotin til regulering af ketonstoffer
EP1637163A1 (en) 2004-09-21 2006-03-22 Andreas Kluge Indicator of therapeutic compliance
JP5177785B2 (ja) 2004-11-02 2013-04-10 味の素株式会社 周術期患者用薬剤
PT1824563E (pt) 2004-11-26 2010-05-17 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
WO2006083381A2 (en) 2004-12-03 2006-08-10 University Of Maryland, Baltimore Composition for treating sulfur mustard toxicity and methods of using same
JPWO2006061992A1 (ja) 2004-12-10 2008-06-05 味の素株式会社 肝疾患予防・治療用組成物
JP5604673B2 (ja) 2005-01-31 2014-10-15 隆宣 山本 中枢神経系の疲労回復又は疲労予防のための組成物
CN1679941A (zh) 2005-02-02 2005-10-12 北京阜康仁生物制药科技有限公司 一种由牛磺酸和治疗肝病的药物组成的复方制剂及其制备方法
CA2537647A1 (en) 2005-03-01 2006-09-01 Six Star Formulations Ltd. Supplemental dietary composition for supporting muscle growth, recovery and strength
JP2008533078A (ja) 2005-03-15 2008-08-21 ネステク ソシエテ アノニム ビタミンｃのバイオアベイラビリティを調節するための栄養組成物
AU2006226935B2 (en) 2005-03-21 2011-07-07 Abbott Laboratories Amino acid composition for improving glucose tolerance
EP1865944B1 (en) 2005-03-29 2018-08-29 Ajinomoto Co., Inc. Amino acid-containing composition used for preventing or remedying decrease in skeletal muscle mass of aged people, comprising L-leucine
AU2006231557B2 (en) 2005-04-06 2010-09-09 Société des Produits Nestlé S.A. A method and composition for nutritionally improving glucose control and insulin action
US8993627B2 (en) 2005-04-21 2015-03-31 Sentient Lifesciences, Inc. N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
EP1890688A2 (en) 2005-06-14 2008-02-27 Nestec S.A. Nutritional method
EP1908492A4 (en) 2005-06-22 2008-12-10 Ajinomoto Kk METABOTROPIC GLUTAMATE RECEPTOR ACTIVATOR
US20100104548A1 (en) 2005-06-24 2010-04-29 Albert Einstein College Of Medicine Of Yeshiva University Modulation of amino acid metabolism in the hypothalamus
JPWO2007004613A1 (ja) 2005-07-01 2009-01-29 味の素株式会社 炎症性腸疾患治療薬及びＴＮＦ−α産生抑制剤
JP2007023921A (ja) * 2005-07-19 2007-02-01 Toyota Motor Corp 内燃機関の制御装置
EP1938813A1 (en) 2005-08-04 2008-07-02 Ajinomoto Co., Inc. Agent for reduction of oxidized albumin level
WO2007018278A1 (ja) 2005-08-05 2007-02-15 Ajinomoto Co., Inc. 肝癌発生・進展抑制剤
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
BRPI0615381A2 (pt) 2005-08-26 2011-05-17 Nestec Sa composições e métodos para melhorar a integridade vascular funcional, a sobrevivência celular e reduzir a apoptose na isquemia ou após um episódio isquêmico no cérebro
EP1774973A1 (en) 2005-10-12 2007-04-18 Nutricia N.V. Leucine rich composition
WO2007053390A2 (en) 2005-10-28 2007-05-10 Nestec S.A. Methods for the use of branched chain amino acids
US20080317886A1 (en) 2005-11-03 2008-12-25 Sparkman Dennis R Compositions for Preventing and Reducing Delayed Onset Muscle Soreness
CA2637806A1 (en) 2005-11-07 2007-05-18 Russell M. Jaffe Compositions for regulating metabolic disorders and methods of use thereof
SG163600A1 (en) 2005-11-30 2010-08-30 Nestec Sa Methods for the treatment of muscle loss
EP2082738B1 (en) 2005-12-19 2015-09-16 Abbott Laboratories Use of beta-hydroxy-beta-methylbutyrate to treat asthma
EP2340724A3 (en) 2006-01-09 2012-02-29 Nestec S.A. Treatment of stressed patients
EP1983849B1 (en) 2006-01-20 2013-04-03 Innova Food AB A food composition comprising amino acids
ATE475328T1 (de) 2006-01-31 2010-08-15 Nestec Sa Nährstoffzusammensetzung für säuglinge mit niedrigem geburtsgewicht
WO2007133642A1 (en) 2006-05-11 2007-11-22 Garcia Ramon D Sport drink containing amino acids and carbohydrates
JP5100033B2 (ja) 2006-05-16 2012-12-19 大塚製薬株式会社 消化管及び腎臓の萎縮抑制剤
US20070286909A1 (en) 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
JP2008050277A (ja) 2006-08-22 2008-03-06 Ajinomoto Co Inc 鉄欠乏性貧血症治療用組成物
US9192593B2 (en) 2006-08-30 2015-11-24 Ajinomoto Co., Inc. Amino-acid containing composition for inhibiting accumulation of fat
CA2666871C (en) 2006-10-19 2011-08-30 Nestec S.A. Long term feed - cancer patient
US20080102137A1 (en) 2006-10-31 2008-05-01 Guffey Manning V R Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization
GB0624879D0 (en) 2006-12-14 2007-01-24 Shs Int Ltd Treatment of pervasive development disorders
EP1932437A1 (en) 2006-12-15 2008-06-18 Nestec S.A. Infant formula
CN100518815C (zh) 2007-02-15 2009-07-29 北京苏里曼医药科技有限公司 一种氨基酸组合物
US20080268038A1 (en) 2007-04-26 2008-10-30 Wolfe Robert R Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength
CN101332209B (zh) 2007-06-25 2010-12-08 三菱制药（广州）有限公司 治疗肝性脑病的复方氨基酸注射液
US8455531B2 (en) 2007-09-18 2013-06-04 Thermolife International, Llc Amino acid compositions
US7777074B2 (en) 2007-09-18 2010-08-17 Thermolife International, Llc Amino acid compounds
US8466187B2 (en) 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
KR100970664B1 (ko) 2007-10-11 2010-07-15 한화제약주식회사 Ｌ-오르니틴-ｌ-아스파테이트를 함유한 겔제의 제조방법 및그 겔제
EP2057905A1 (en) 2007-11-12 2009-05-13 TIMA Foundation Composition for moderating Triglyceride and Cholesterol Levels
JP2011504879A (ja) 2007-11-26 2011-02-17 ネステク ソシエテ アノニム 二本鎖ｒｎａ依存性タンパク質キナーゼの活性化を阻害し腫瘍成長を阻害する組成物及び方法
CN101214050B (zh) 2007-12-28 2011-08-31 叶高山 一种具有提神、抗疲劳、醒酒功能的保健饮料
CN105267969A (zh) 2008-01-04 2016-01-27 雀巢产品技术援助有限公司 包含不饱和脂肪酸和一氧化氮释放化合物的组合物及其用于增强认知和相关功能的用途
US7790688B2 (en) 2008-01-11 2010-09-07 Healthspan Solutions, Llc Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly
US20090186098A1 (en) 2008-01-18 2009-07-23 Jose Briceno Sports drink composition
EP2095728B1 (en) 2008-01-25 2011-09-07 Cesar Gallia s.r.l. Amino acid concentrate in aqueous gel and fatigue-relieving drink obtainable by diluting said concentrate in water
US8716249B2 (en) 2008-01-31 2014-05-06 Energy Light Llc Compositions and methods for improving cardiovascular health
MX2010008544A (es) 2008-02-05 2011-03-21 Healthspan Solutions Llc Sistemas para y metodos de uso de nutricion terapeutica para el manejo de condiciones de salud asociadas con la edad y especificas de los adultos mayores.
CN101939011B (zh) 2008-02-07 2012-10-10 雀巢产品技术援助有限公司 用于影响由剧烈的体力活动中恢复的组合物和方法
EP2098124A1 (en) 2008-03-03 2009-09-09 Nestec S.A. Carbohydrate gel
EP2098126A1 (en) 2008-03-03 2009-09-09 Nestec S.A. Carbohydrate Bar
CN102316730A (zh) 2008-05-09 2012-01-11 天雅瑞药业有限公司 用于减轻全身性炎症和/或血管炎症的n-乙酰半胱氨酸(nac)的控释
WO2009149196A1 (en) 2008-06-04 2009-12-10 Phenolics, Llc. Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same
US20100021573A1 (en) * 2008-07-22 2010-01-28 Michael J Gonzalez Compositions and methods for the prevention of cardiovascular disease
EP2165713B1 (en) 2008-09-19 2012-11-14 Nestec S.A. Whey and thymus function
MX2011002982A (es) 2008-09-19 2011-04-11 Nestec Sa Soporte nutricional del sistema inmunologico durante el tratamiento anti-cancer.
JPWO2010050168A1 (ja) 2008-10-27 2012-03-29 味の素株式会社 バリン、イソロイシン、ロイシン固溶体およびその製造方法
US8362080B2 (en) 2008-12-18 2013-01-29 Baylor College Of Medicine Increasing glutathione levels for therapy
WO2010081079A2 (en) 2009-01-12 2010-07-15 Biokier Inc. Composition and method for treatment of diabetes
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
US20120178672A1 (en) 2009-03-18 2012-07-12 Wolfe Robert R Compositions and Methods for Sparing Muscle in Renal Insufficiency and During Hemodialysis
WO2010108542A1 (en) 2009-03-25 2010-09-30 Nestec S.A. A natural taste enhancing savoury base and a process for its preparation
SI2413924T1 (en) 2009-04-03 2018-01-31 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
WO2010126353A1 (en) 2009-04-27 2010-11-04 N.V. Nutricia Pea-based protein mixture and use thereof in a liquid nutritional composition suitable for enteral feeding
US8703719B1 (en) 2009-05-18 2014-04-22 Bio-Engineered Supplements And Nutrition, Inc. Method and composition for improved muscle performance
EP3517110A1 (en) 2009-06-08 2019-07-31 UCL Business PLC Treatment of inflammation using l-ornithine phenylacetate
WO2010143939A1 (en) 2009-06-09 2010-12-16 N.V. Nutricia Nutrition for improving muscle strength in elderly
CN102647990A (zh) 2009-07-20 2012-08-22 雀巢产品技术援助有限公司 减少功能状态损失的方法
WO2011030104A1 (en) 2009-09-09 2011-03-17 Rajiv Jalan Phenylacetate and/or phenylbutyrate (not ornithine) for reducing portal blood pressure
CN101664384B (zh) 2009-09-18 2011-09-14 杭州市第六人民医院 N-乙酰半胱氨酸盐木糖醇注射液及其制备方法和应用
JP2013505936A (ja) 2009-09-23 2013-02-21 バイオキアー・インコーポレイテッド 糖尿病の治療のための組成物および方法
WO2011044230A2 (en) 2009-10-06 2011-04-14 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions
WO2011043647A1 (en) 2009-10-09 2011-04-14 N.V. Nutricia Amino acid composition with improved dispersibility
EP2327316B1 (en) 2009-11-29 2016-11-16 Premier Nutrition Corporation Method of enhancing muscle protein synthesis
PL2327315T3 (pl) 2009-11-29 2014-03-31 Nestec Sa Protokoły dawkowania dla zwiększenia syntezy białka u osób aktywnych
WO2011078654A1 (en) 2009-12-24 2011-06-30 N.V. Nutricia Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis
JP2011132174A (ja) 2009-12-24 2011-07-07 Kirin Holdings Co Ltd 持久力向上剤
WO2011097273A1 (en) * 2010-02-02 2011-08-11 Martek Biosciences Corporation Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl lcystenine
US8853148B2 (en) 2010-03-12 2014-10-07 Nestec S.A. Compositions for masking the flavor of nutrients and methods for making same
WO2011119023A1 (en) 2010-03-26 2011-09-29 N.V. Nutricia Low protein infant formula with increased essential amino acids
CA2796936A1 (en) 2010-04-26 2011-11-10 Nestec S.A. Nutritional compositions and methods for weaning from parenteral nutrition to enteral nutrition
US8840950B2 (en) 2010-05-26 2014-09-23 Jacqueline M. Hibbert Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore
WO2012005568A1 (en) 2010-07-07 2012-01-12 N.V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
KR101213825B1 (ko) 2010-07-16 2012-12-18 서울대학교산학협력단 세린을 유효성분으로 함유하는 지방간 질환의 예방 및 치료용 조성물
MY173215A (en) 2010-07-21 2020-01-06 Cumberland Pharmaceuticals Inc Acetylcysteine compositions and methods of use thereof
US20120020947A1 (en) 2010-07-22 2012-01-26 Northern Innovations And Formulations Corp. Compositions and methods for increasing lean muscle mass after exercise
CN101912394B (zh) 2010-08-06 2013-11-06 岳茂兴 一种用于治疗凝血障碍出血的药物组合物及其用途
NZ609191A (en) 2010-10-06 2015-06-26 Ocera Therapeutics Inc Methods of making l-ornithine phenyl acetate
EP2444083A1 (en) 2010-10-21 2012-04-25 Nestec S.A. Cysteine and food intake
CN103338658A (zh) 2010-12-22 2013-10-02 雅培制药有限公司 含有β-羟基-β甲基丁酸钙和共轭亚油酸的营养型产品
CA2821312A1 (en) 2010-12-27 2012-07-05 Abbott Laboratories Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate
WO2012097061A1 (en) 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for improving skeletal muscle protein metabolism
ES2828479T3 (es) 2011-01-25 2021-05-26 Nestle Sa Métodos y composiciones para tratar, reducir o prevenir el deterioro del sistema visual de los animales
RU2491062C2 (ru) * 2011-03-16 2013-08-27 Общество С Ограниченной Ответственностью "Биотехнологии Пущино" Композиции протекторов острых и хронических печеночных энцелопатий и способ лечения острых и хронических печеночных энцелопатий
JP2014515011A (ja) 2011-03-18 2014-06-26 ネステク ソシエテ アノニム 加齢に伴う疾病を改善するのに有用な組成物及び方法
WO2012135499A1 (en) 2011-03-31 2012-10-04 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
CN102327259A (zh) 2011-03-31 2012-01-25 姜国辉 具有显著化学性肝损伤保护功能的复合生物制剂
CN103458889A (zh) 2011-04-12 2013-12-18 雀巢产品技术援助有限公司 包括支链脂肪酸的用于创口愈合的营养组合物
RU2013151090A (ru) 2011-04-18 2015-05-27 Нестек С.А. Питательные композиции, содержащие альфа-гидроксиизокапроновую кислоту и эйкозапентаеновую кислоту
US20120270860A1 (en) 2011-04-19 2012-10-25 Gihyun Yoon Methods for treating or preventing alcohol-related disorders or craving-related disorders
RU2013151680A (ru) 2011-04-21 2015-05-27 Нестек С.А. Питательные композиции для улучшения выступления, способы их получения и применения
US8828426B2 (en) 2011-06-07 2014-09-09 Zx Pharma, Llc Multiparticulate L-carnitine compositions and related methods
US20140135396A1 (en) 2011-07-05 2014-05-15 Beth Israel Deaconess Medical Center, Inc. Treatment of Acetaminophen-Induced Liver Damage by the Administration of Modulators of Nitric Oxide
JP6431670B2 (ja) 2011-08-08 2018-11-28 味の素株式会社 筋肉疲労の回復を促進するためのアミノ酸含有組成物
EP2744356A4 (en) 2011-08-19 2015-05-27 Musclepharm Corp COMPOSITIONS AND METHODS FOR INHIBITING INCOUNTERANCE IN ANIMALS
EP2574333B1 (en) 2011-09-27 2017-01-11 Friulchem SpA N-acetylcysteine effervescent tablet and its therapeutical applications
EP2580967A1 (en) 2011-10-11 2013-04-17 Nestec S.A. Accelerating muscle recovery after immobilization-induced muscle atrophy
EP2583565A1 (en) 2011-10-21 2013-04-24 Nestec S.A. Use of whey protein micelles for enhancing energy expenditure and satiety
EP2583563A1 (en) 2011-10-21 2013-04-24 Nestec S.A. Whey protein micelles against muscle atrophy and sarcopenia
WO2013075095A1 (en) 2011-11-18 2013-05-23 The Board Of Trustees Of The University Of Arkansas Use of amino acid supplementation for improved muscle recovery
BR112014011898A2 (pt) 2011-11-21 2017-05-16 Emmaus Medical Inc métodos e composições para o tratamento de diabetes e sintomas relacionados
JP5788527B2 (ja) 2011-12-02 2015-09-30 味の素株式会社 キナーゼ阻害剤の副作用低減剤
AU2013210373A1 (en) 2012-01-19 2014-09-04 Shoichi Shirotake Antibacterial agent against plant disease-causing bacteria
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
WO2013188258A1 (en) 2012-06-11 2013-12-19 Abbott Laboratories Use of hmb to improve health outcomes for hospitalized patients
CA2877811C (en) 2012-07-31 2019-07-23 Nestec S.A. Nutritional composition for promoting musculoskeletal health in patients with inflammatory bowel disease (ibd)
BR112015005381A2 (pt) 2012-09-14 2017-07-04 Nestec Sa composições de sabor com sabor e prazo de validade do sabor melhorados
US8747921B2 (en) 2012-09-19 2014-06-10 Quality Ip Holdings, Inc. Methods for improving health in humans
US9198889B2 (en) 2012-09-19 2015-12-01 Quality IP Holdings, LLC Methods for treating post-traumatic stress disorder
US9066953B2 (en) 2012-09-20 2015-06-30 Quality IP Holdings, LLC Methods for increasing endurance and fat metabolism in humans
CN102961377A (zh) 2012-11-08 2013-03-13 湖北一半天制药有限公司 复方氨基酸注射液（20aa）的制备方法
ES2633769T3 (es) 2012-12-04 2017-09-25 Nestec S.A. Hexanoilglicina como biomarcador para la predisposición al aumento de peso y a la obesidad
JP2016509003A (ja) 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 組成物および方法
KR20190040091A (ko) 2013-03-11 2019-04-16 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 폐 기능의 개선 및 방사선 유발된 폐 합병증의 예방 및/또는 치료를 위한 물질 및 방법
BR112015023310A2 (pt) 2013-03-15 2017-07-18 Nusirt Sciences Inc composições, métodos e kits para redução de níveis lipídicos
CA2907667A1 (en) 2013-03-26 2014-10-02 Premier Nutrition Corporation Methods for enhancing muscle protein synthesis following concurrent training
US20160051814A1 (en) 2013-04-15 2016-02-25 Nestec S.A. Use of whey protein in combination with electrical muscle stimulation
ES2844199T3 (es) 2013-04-16 2021-07-21 Childrens Hospital Philadelphia Composiciones y métodos para el tratamiento de lesiones cerebrales
US20140357576A1 (en) 2013-05-31 2014-12-04 Nestec S.A. Methods for enhancement of muscle protein synthesis
BR112015032572B1 (pt) 2013-06-28 2021-04-13 Société des Produits Nestlé S.A. Suplemento pré-exercício para cães
EP3738590A1 (en) 2013-07-31 2020-11-18 Leeds Beckett University Dietary supplement comprising amino acids for the treatment of sarcopenia
US20180125926A1 (en) 2013-09-25 2018-05-10 Axcella Health Inc. Compositions and Formulations and Methods of Production and Use Thereof
JP2016537402A (ja) 2013-09-25 2016-12-01 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． 癌の処置における、腫瘍形成、癌細胞の増殖および浸潤の予防および低減のための組成物および配合物、ならびにその生成方法および使用方法
WO2015052086A1 (en) 2013-10-09 2015-04-16 Nestec S.A. Compositions comprising citrulline and leucine and their use in the treatment of diabetes and metabolic syndrome
EP3060231A1 (en) 2013-10-23 2016-08-31 The Whitehead Institute for Biomedical Research Mtorc1 modulation by amino acids and uses thereof
RU2016138136A (ru) 2014-02-27 2018-04-02 Нусерт Сайенсиз, Инк. Композиции и способы уменьшения или профилактики жировой дистрофии печени
GB2523578A (en) 2014-02-28 2015-09-02 Daniel Nelson A nutritional supplement
WO2015161448A1 (en) 2014-04-22 2015-10-29 Wuhan Ll Science And Technology Development Co., Ltd. Ornithine-containing or aspartate-containing compositions and the uses thereof
CN105092753B (zh) 2014-05-20 2016-09-07 中国科学院大连化学物理研究所 组合型胺类代谢标志物的应用及试剂盒
WO2016003263A1 (en) 2014-07-01 2016-01-07 N.V. Nutricia Amino acid based diet with improved taste
US10217645B2 (en) 2014-07-25 2019-02-26 Versum Materials Us, Llc Chemical mechanical polishing (CMP) of cobalt-containing substrate
US20160158305A1 (en) 2014-09-19 2016-06-09 Chip E. Thomson Additives and supplements
JP6826033B2 (ja) 2014-10-14 2021-02-03 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 高齢男性の筋機能の改善
US10039735B2 (en) 2014-11-24 2018-08-07 Ucl Business Plc Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
CN106999390A (zh) 2014-12-04 2017-08-01 专业营养股份公司 用于皮肤结缔组织中纤维弹性蛋白恢复的基于氨基酸的组合物
WO2016094316A1 (en) 2014-12-08 2016-06-16 Synaptamine, Inc. Anti-rds compounds and method of manufacture and administration thereof to induce dopamine homeostatis
EP3034074A1 (en) 2014-12-18 2016-06-22 Universitat De València, Estudi General Compound for treatment of myotonic dystrophy type 1
AU2016208545A1 (en) 2015-01-23 2017-06-15 Société des Produits Nestlé S.A. Treatment or prevention of inflammation using serine
JP2018504405A (ja) 2015-01-23 2018-02-15 ネステク ソシエテ アノニム Ｉｂｄ患者の治療に有用な栄養組成物
US10768169B2 (en) 2015-01-23 2020-09-08 Societe Des Produits Nestle S.A. Method for determining the distinctive nutritional requirements of a patient
US20170368026A1 (en) 2015-01-23 2017-12-28 Nestec S.A. Promotion of healing of intestinal mucosa using proline, serine and threonine
JP6847668B2 (ja) 2015-01-27 2021-03-24 昇一 城武 ナノ粒子を有効成分とする皮膚炎の治療又は予防剤
JP2018510129A (ja) 2015-02-13 2018-04-12 ネステク ソシエテ アノニム 手術によって誘発される悪液質並びに／又は骨髄由来サプレッサー細胞及び炎症性サイトカインの発現の処置又は予防
US20180036270A1 (en) 2015-02-13 2018-02-08 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College A method of protecting against carbonyl stress induced ischemia-reperfusion injury in the diabetic brain via administration of n-acetylcysteine
FR3032883B1 (fr) 2015-02-24 2017-03-17 International Nutrition Res Company Composition pour la prevention et le traitement de la steatose et de la steatohepatite metaboliques
US20160302451A1 (en) 2015-04-16 2016-10-20 Michael Hudnall Medical Food for Patients with Chronic Liver Disease
KR20180006904A (ko) 2015-04-20 2018-01-19 오세라 테라퓨틱스, 아이엔씨. L-오르니틴 페닐아세테이트의 제형
US10123985B2 (en) 2015-06-08 2018-11-13 Whitehead Institute For Biomedical Research Therapeutic strategies for treating mitochondrial disorders
AU2016281870B2 (en) 2015-06-22 2020-09-10 Société des Produits Nestlé S.A. Compositions and methods for enhancing neurogenesis in animals
CN107810264B (zh) 2015-06-30 2022-08-05 雀巢产品有限公司 适于保护微生物的组合物
CA3185891A1 (en) 2015-07-15 2017-01-19 Unigen, Inc. Compositions, methods, and medical compositions for treatment of and maintaining the health of the liver
CA2995154C (en) 2015-08-14 2023-09-12 Nestec S.A. Semi-moist food compositions that maintain soft texture
HK1249434A1 (zh) 2015-08-18 2018-11-02 Ocera Therapeutics, Inc. 使用与苯乙酸盐和苯丁酸盐中的至少一种组合的l-鸟氨酸治疗和预防肌肉损失
WO2017033272A1 (ja) 2015-08-25 2017-03-02 昇一 城武 優れた植物病害防除効果を有する菌類用抗菌剤
US20170079897A1 (en) 2015-09-20 2017-03-23 Matthew Brissette MINUS Composition for hair application and methods of hair care
HK1257679A1 (zh) 2015-09-25 2019-10-25 Ocera Therapeutics, Inc. 使用l-鸟苷酸与苯乙酸根和苯基丁酸根中至少一种的结合治疗和预防神经元细胞损失
US20170196944A1 (en) 2015-09-28 2017-07-13 Robert Portman Method to reduce muscle atrophy following orthopedic surgery
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
KR20250023993A (ko) 2015-11-13 2025-02-18 오세라 테라퓨틱스, 아이엔씨. L-오르니틴 페닐아세테이트의 제제
EP3377077A1 (en) 2015-11-20 2018-09-26 Nestec S.A. Methods using whey protein to improve or maintain muscle quality
EP3395341B1 (en) 2015-12-21 2025-02-05 Nanjing Jianrong Bio-Technology Co., Ltd. Composition for treating motor neuron diseases and use thereof
US20190000866A1 (en) 2016-01-08 2019-01-03 Colonaryconcepts Llc Food based delivery of therapeutic agent for treatment of hepatic encephalopathy
GB201600990D0 (en) 2016-01-19 2016-03-02 Abbott Lab Pharmaceutical or nutritional combination
EP3454665A4 (en) 2016-05-11 2020-02-19 Tsubo Solutions Pty Ltd CONFECTIONERY PRODUCT
AU2017270131B2 (en) 2016-05-27 2023-03-09 Société des Produits Nestlé S.A. Nutritional composition for treating or preventing impaired mobility
PL238958B1 (pl) 2016-06-29 2021-10-25 Olimp Laboratories Spolka Z Ograniczona Odpowiedzialnoscia Kompozycja aminokwasowa do stosowania przed wysiłkiem fizycznym
US20180015122A1 (en) 2016-07-14 2018-01-18 Companion Supplements, LLC Pharmaceutical composition effective in preventing adverse effects associated with the use of glucocorticoids
US11033522B2 (en) 2016-08-09 2021-06-15 David C Scott Free amino acid preparation and uses thereof
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
JOP20190147A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض واضطرابات العضلات
SE540582C2 (en) 2016-12-22 2018-10-02 Scandibio Therapeutics Ab Substances for treatment of fatty liver-related conditions
CN106632605B (zh) 2016-12-22 2020-06-16 浙江海洋大学 利用金枪鱼下脚料制备的具有肝损伤修复作用的活性肽
CN110392568A (zh) 2017-01-19 2019-10-29 耳科制药公司 N-乙酰半胱氨酸的制剂及其用途
WO2018201024A1 (en) 2017-04-28 2018-11-01 Axcella Health Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
CN107242552A (zh) 2017-07-07 2017-10-13 上海东锦食品集团有限公司 具有缓解体力疲劳及增强免疫力功能的保健食品组合物
US10682325B2 (en) 2017-08-14 2020-06-16 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
CN111295186A (zh) 2017-08-14 2020-06-16 胺细拉健康公司 用于治疗神经元损伤的氨基酸组合物
CN108041501A (zh) 2017-12-22 2018-05-18 北京康比特体育科技股份有限公司 一种促进疲劳恢复的蛋白组合物及其制备方法
CN112839712A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于减少或治疗发炎的组合物和方法
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
WO2019246221A1 (en) 2018-06-20 2019-12-26 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders
BR112020025702A2 (pt) 2018-06-20 2021-03-16 Axcella Health Inc. Composições para terapia e saúde contendo aminoácidos com gosto amargo
JP2021527671A (ja) 2018-06-20 2021-10-14 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． インスリン抵抗性及び代謝疾患の軽減又は治療のための組成物及び方法
JP2021527670A (ja) 2018-06-20 2021-10-14 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． 筋肉中の脂肪浸潤の治療のための組成物及び方法
MA52957A (fr) 2018-06-20 2021-04-28 Axcella Health Inc Procédés de fabrication de compositions d'acides aminés
JP2021527669A (ja) 2018-06-20 2021-10-14 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． 線維症の軽減又は治療のための組成物及び方法
CN108524453A (zh) 2018-07-05 2018-09-14 扬子江药业集团广州海瑞药业有限公司 一种门冬氨酸鸟氨酸的药物组合物

Also Published As

Publication number Publication date
PE20191136A1 (es) 2019-09-02
CN110087647B (zh) 2023-06-16
TWI777999B (zh) 2022-09-21
US11602511B2 (en) 2023-03-14
US10201513B2 (en) 2019-02-12
US10471034B2 (en) 2019-11-12
JP2020504108A (ja) 2020-02-06
US20190105294A1 (en) 2019-04-11
US20180169045A1 (en) 2018-06-21
BR112019012529A2 (pt) 2019-11-19
CL2019001686A1 (es) 2019-08-30
JP2023029946A (ja) 2023-03-07
MX2019007351A (es) 2019-09-05
US11129804B2 (en) 2021-09-28
IL284371A (en) 2021-07-29
CO2019006291A2 (es) 2019-06-28
TW201834645A (zh) 2018-10-01
AU2017382170A1 (en) 2019-06-13
US20180207118A1 (en) 2018-07-26
US20180169044A1 (en) 2018-06-21
AU2017382170B2 (en) 2023-11-30
MA51451A (fr) 2019-10-23
CN110087647A (zh) 2019-08-02
US10238617B2 (en) 2019-03-26
IL267480A (en) 2019-08-29
ECSP19043710A (es) 2019-07-31
EP3554492A1 (en) 2019-10-23
IL267480B (en) 2021-07-29
JOP20190146A1 (ar) 2019-06-18
MX2022013517A (es) 2022-11-16
IL296614A (en) 2022-11-01
ZA201903580B (en) 2021-08-25
PH12019501414A1 (en) 2019-10-28
US20240041810A1 (en) 2024-02-08
SG10201913946WA (en) 2020-03-30
CA3046551A1 (en) 2018-06-28
CN115814053A (zh) 2023-03-21
US20200330417A1 (en) 2020-10-22
US20180296516A1 (en) 2018-10-18
IL284371B (en) 2022-10-01
IL284371B2 (en) 2023-02-01
KR20190099242A (ko) 2019-08-26
WO2018118941A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
CU20190058A7 (es) Composiciones de aminoácidos relacionadas con mejoras de la función hepática
CL2016002772A1 (es) Composiciones de insulina de rápida acción
CU20190006A7 (es) Composiciones para inhibir masp-3
CL2018002081A1 (es) Inhibidores de la proteína quinasa 1 que interactua con el receptor
CL2018000106A1 (es) Moléculas de anticuerpo que se unen a cd45
CO7111287A2 (es) Composiciones plaguicidas y procesos relacionados
MX2013003365A (es) Composicion farmaceutica.
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
EA201690613A1 (ru) Улучшенные составы на основе аденовирусов
UY34779A (es) Anticuerpos anti-il-23 y composiciones farmacéuticas que los contienen
GT201200165A (es) Triazolopiridinas
EA201591961A1 (ru) Ингибиторы акк и их применение
EA201591959A1 (ru) Ингибиторы акк и их применение
BR112018012262A2 (pt) composições de interleucina-15 e seus usos
EA201591962A1 (ru) Ингибиторы акк и их применение
BR112017022209A2 (pt) composição aquosa que compreende éster de ácido omega- aminocarboxílico e álcool graxo e seu uso
EP4609911A3 (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
BR112015025852A2 (pt) as formulações de oxabicicloheptanos e oxabicicloheptenos
MX2020001885A (es) Formulaciones de daptomicina.
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
BR112015023387A2 (pt) composições lipídicas de racecodotril
BR112017013770A2 (pt) composições de inibidor de nitrificação microencapsuladas
AR104591A1 (es) Piroglutamato de vortioxetina
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t